Prostaglandin E₂ from *Candida albicans* Stimulates the Growth of *Staphylococcus aureus* in Mixed Biofilms

Jan Krause*, Gernot Geginat, Ina Tammer*

Institute of Medical Microbiology, Hospital Control and Prevention, Otto-von-Guericke University, Magdeburg, Germany

* Current address: Department for Abdominal, Vascular, Thoracic and General Surgery, AMEOS Hospital, Aschersleben, Germany

* ina.tammer@med.ovgu.de

**Abstract**

**Background**

Previous studies showed that *Staphylococcus aureus* and *Candida albicans* interact synergistically in dual species biofilms resulting in enhanced mortality in animal models.

**Methodology/Principal Findings**

The aim of the current study was to test possible candidate molecules which might mediate this synergistic interaction in an *in vitro* model of mixed biofilms, such as farnesol, tyrosol and prostaglandin (PG) E₂. In mono-microbial and dual biofilms of *C. albicans* wild type strains PGE₂ levels between 25 and 250 pg/mL were measured. Similar concentrations of purified PGE₂ significantly enhanced *S. aureus* biofilm formation in a mode comparable to that observed in dual species biofilms. Supernatants of the null mutant deficient in PGE₂ production did not stimulate the proliferation of *S. aureus* and the addition of the cyclooxygenase inhibitor indomethacin blocked the *S. aureus* biofilm formation in a dose-dependent manner. Additionally, *S. aureus* biofilm formation was boosted by low and inhibited by high farnesol concentrations. Supernatants of the farnesol-deficient *C. albicans* ATCC10231 strain significantly enhanced the biofilm formation of *S. aureus* but at a lower level than the farnesol producer SC5314. However, *C. albicans* ATCC10231 also produced PGE₂ but amounts were significantly lower compared to SC5314.

**Conclusion/Significance**

In conclusion, we identified *C. albicans* PGE₂ as a key molecule stimulating the growth and biofilm formation of *S. aureus* in dual *S. aureus/C. albicans* biofilms, although *C. albicans* derived farnesol, but not tyrosol, may also contribute to this effect but to a lesser extent.
Introduction

The first study suggesting a specific interaction between *Staphylococcus* (*S.*) *aureus* and *Candida* (*C.*) *albicans* was published in 1976 [1]. Since then, a number of studies corroborated this result and showed a synergistic interaction of *S. aureus* and *C. albicans* with enhanced mortality in animal models [2-4].

*In vitro* studies of complex microbial communities show that intra-species and inter-species interactions are mediated via small molecules released into the extracellular environment, i.e. quorum sensing molecules, extracellular virulence factors, or secondary metabolites [5-7].

*Candida albicans* regulates virulence traits through the production of at least two quorum-sensing (QS) signal molecules, *E,E*-farnesol and tyrosol, both affecting dimorphism and biofilm formation in *C. albicans* [8-10]. Furthermore, *C. albicans* farnesol down-regulates the production of pyocyanin in *Pseudomonas* (*P.*) *aeruginosa* [11] and inhibits biofilm formation and lipase activity in *S. aureus* [12,13].

*Candida albicans* is a commensal microorganism in healthy individuals but is capable of causing disseminated or chronic infections when the host mucosal barrier is breached and the immune response is inadequate. *In vivo*, inflammation is mediated by the production of eicosanoids including prostaglandins and leukotrienes. Prostaglandin E2 (PGE2), an oxygenated metabolite of arachidonic acid, is known to regulate the activation, maturation, cytokine release and migration of the mammalian cells, particularly those involved in innate immunity [14-18]. Interestingly, *C. albicans* produces authentic PGE2 from external arachidonic acid [19], which is upregulated during biofilm formation suggesting that PGE2 may represent a significant virulence factor in biofilm-associated infections.

In order to evaluate the possible effect of PGE2 on bacterial biofilms, we established a *S. aureus/C. albicans* dual species biofilm model. Using this model we were able to replace the stimulatory activity of *C. albicans* on *S. aureus* by synthetic purified PGE2, suggesting that this metabolite plays an important role in the interaction of *S. aureus* and *C. albicans* in biofilms.

Material and Methods

*Staphylococcus aureus* and *C. albicans* strains

The following strains were used in this study: *Staphylococcus* (*S.*) *aureus* 31883 small colony variant (SCV) strain isolated from a sputum sample of a patient suffering from cystic fibrosis; *S. aureus* 19552 clinical isolate derived from the throat of a cystic fibrosis patient (non-SCV phenotype); *Candida* (*C.*) *albicans* 31883 isolated from a sputum sample of a patient suffering from cystic fibrosis; *C. albicans* ATCC10231 wild type (wt) strain (laboratory strain; farnesol-deficient); *C. albicans* SC5314 wt strain (laboratory strain; farnesol producer, [20]); *C. albicans* M35 (prototrophic reference strain; same as CAF2-1, but *ura3-*/URA3 [21]); *C. albicans* M134 (prototrophic reference strain; same as CAI4, but *ura3-*/::URA3/RPS [22]; further *ura3-*/::URA3 [23]; further *ura3-*/::URA3 [23]; further *ura3-*/::URA3 [23]).

Clinical isolates were cultured from routine diagnostic samples which were sent to the Institute of Medical Microbiology. The samples were processed in the diagnostic laboratory under the special guidance of the author as described below. After homogenization with sterile saline (1:1) the sputum samples were plated on various agar plates and incubated at 37°C and at 30°C for two days, respectively, and at 25°C for further three days. The throat swabs were processed in a similar manner without homogenization. After visible growth the colonies were identified by the use of mass spectrometry (Vitek2 MS; Biomerieux, France) according to the instructions of the manufacturer. All strains identified from patients with cystic fibrosis were routinely stored at -70°C using the Microbank system as recommended by the manufacturer (Bestbion; Colonia, Germany).
For the use in this study, clinical strains were cultured from the Microbank system on Columbia agar plates containing 5% sheep blood (Beckton Dickinson) and incubated overnight at 37°C. Subcultures on blood agar plates were incubated for further 24h under the same conditions. From these subcultures glycerin stocks (99.9%; Calbiochem, Heidelberg, Germany) were prepared and stored at -70°C until further use.

**Dual S. aureus/C. albicans biofilms**

Three to five S. aureus colonies grown from glycerin stocks were inoculated in 5mL trypcase soy broth (TSB-T; Biomerieux, Nürtingen, Germany) and incubated overnight at 37°C with agitation of 180 rpm. C. albicans cells from glycerin stocks were propagated overnight in 100mL Yeast peptone dextrose (YPD) medium (Sigma, Hannover; Germany) at 30°C on an orbital shaker at 180 rpm. Under these conditions all strains grow in the budding yeast phase. Candida cells were harvested by centrifugation, washed twice in sterile phosphate buffered saline (1xPBS; Sigma), re-suspended and adjusted to a cellular density equivalent to 3x10^6 cells/mL. S. aureus cells were adjusted to an optical density of 0.02 in RPMI1640 using a spectrophotometer (Eppendorf, Hamburg, Germany) which is equivalent to approximately 3x10^6 cells/ml [24]. One mL of each microbial suspension was added to each well of a 12-well plate (Greiner, Frickenhausen, Germany). Biofilms were incubated in RPMI1640 buffered with HEPES and supplemented with L-glutamine and 10% heat-inactivated fetal bovine serum (FBS; Thermo Fisher Scientific, Schwerte, Germany) for the appropriate time at 37°C with 75 rpm of agitation in humid atmosphere. Medium was changed daily. Under these conditions S. aureus and C. albicans formed stable and reproducible mono-microbial and mixed biofilms which was tested using one-way ANOVA (analysis of variance) as described elsewhere [25,26]. After the appropriate time of incubation supernatants were removed. Biofilms were scraped from the bottom of the wells and homogenized with Sputasol liquid (50 μg/mL; Thermo Fisher) as described by Efthimiadis et al. [27]. Cells were collected by centrifugation (1100xg for 5 min) and washed twice in sterile PBS. The inoculum was confirmed by quantitative culture (serial diluted 10-fold) on mannitol salt agar (MSA2 agar; Biomerieux) after 24h of incubation at 37°C for S. aureus or on Chromagar CANDIDA (BD) after 48h at 30°C for C. albicans.

**Crystal violet staining**

Mono-microbial and mixed biofilms were stained with crystal violet (CV) solution as described by Peeters et al. [28]. Briefly, biofilms cultured in 96-well plates were fixed with methanol. Then, 0.2% crystal violet solution was added to each well and incubated for 20 min at room temperature. Excess CV was removed by washing under running tap water and bounded CV was released by 33% acetic acid (Sigma). Absorbance was measured at 570 nm.

**Determination of the prostaglandin concentration**

Prostaglandin E2 (PGE2) production was measured from supernatants of different mono-microbial and dual biofilms using a monoclonal PGE2 enzyme-linked immunosorbent assay (ELISA; Cayman Chemicals, Ann Arbor, USA) according to the instructions of the manufacturer. Supernatants were collected from the biofilms after the appropriate time point, centrifuged at 8000xg, filtered twice by using a 0.22 μm syringe filter (Roth, Karlsruhe, Germany) and stored at -80°C. To confirm, that the supernatants yielded no living cells of S. aureus and C. albicans, 100 μl of the supernatants were plated onto blood agar plates and incubated for 48h at 37°C and for further 48h at 30°C. All supernatants processed by this method were cell-free. In serum, PGE2 is rapidly degraded into unstable intermediates [19], i.e. 15-keto-13, 14-dihydro-PGE2, which were determined with a PGE2 metabolite kit (Cayman Chemicals).
The PGE\textsubscript{2} metabolite kit converts the unstable intermediates into stable measurable derivatives serving as marker for the PGE\textsubscript{2} production. Background levels of PGE\textsubscript{2} detected in RPMI 1640 with and without FBS were subtracted from experimental samples.

**Purified substances**

Purified tyrosol, farnesol and prostaglandin E\textsubscript{2} (PGE\textsubscript{2}) were purchased from Sigma-Aldrich. Stock solutions of tyrosol (2,4-hydroxyphenylethanol) and farnesol were dissolved in DMSO. PGE\textsubscript{2} stock solution (1mg/mL) was prepared in ethanol and further diluted in 1xPBS. Established 24h old \textit{S. aureus} biofilms were incubated overnight in the presence of the appropriate drugs, biofilms were harvested and the numbers of colony forming units (cfu’s) were determined as described above. Control experiments revealed that DMSO and ethanol did not affect the growth of \textit{S. aureus} and \textit{C. albicans}.

**Inhibitors**

The cyclooxygenase inhibitor indomethacin (Sigma) was dissolved in dimethyl sulfoxide (stock solution 1mM) and further diluted in PBS prior to addition to mixed biofilms. Dual biofilms without supplements or with DMSO alone were used as control. DMSO did not influence the growth of the biofilms.

**Statistical analysis**

Data represent the mean plus the standard deviation of two independent experiments with three intra-assay replicates.

Statistical significance was determined using Student’s t-test with SigmaStat statistical software (version 2.0). \(P\)-values \(\leq 0.05\) were considered statistically significant.

**Ethics statement**

According to the written decision of the clinical research ethics committee of the Otto-von-Guericke University of Magdeburg the current study did not require approval by the local ethics committee because no human material or data attributable to individual patients were used.

**Results**

**Stimulation of \textit{S. aureus} by \textit{C. albicans} in mixed biofilms**

Initial mixed biofilm experiments with clinical strains of \textit{S. aureus} and \textit{C. albicans} showed that biofilm thickness of mixed biofilms was significantly increased compared with \textit{S. aureus} mono-microbial biofilms (Fig 1A).

Mixed biofilms yielded a significantly higher number of \textit{S. aureus} colony forming units (cfu’s) compared to mono-microbial \textit{S. aureus} biofilms with a dramatically increase after 72h of co-culture (Fig 1B).

In order to investigate, if the growth-stimulating effect of \textit{C. albicans} depends on the direct contact of bacteria to the hyphal network, 24h old \textit{S. aureus} biofilms were incubated with cell-free supernatants from \textit{C. albicans} 31883 and SC5314 diluted 1:1 with fresh medium (Fig 2A). The number of cfu’s of \textit{S. aureus} increased 10-fold when supernatants derived from 72h or 96h old \textit{C. albicans} biofilms were added. The strongest increase was observed with supernatants from \textit{C. albicans} SC5314. Remarkably, the stimulatory activity of supernatants was heat-labile. Incubation of \textit{S. aureus} with heat-treated supernatants from \textit{C. albicans} mono-microbial biofilms did not promote the propagation of \textit{S. aureus} (Fig 2B).
Fig 1. Growth kinetics of *S. aureus* in mono-microbial and in dual *S. aureus/C. albicans* biofilms. (a) Biofilm thickness of *S. aureus* 19552 single (open bars) and mixed biofilms with *C. albicans* 31883 wt (clinical strain; striped) or *C. albicans* SC5314 wt (laboratory strain; solid bars) at various time points determined by staining with crystal violet. Total biofilm thickness is expressed as mean of the optical density (OD) measured at a wave length of 570 nm. Shown are the means and standard deviations of two independent experiments with 24 replicates each. (b) Quantification of *S. aureus* 19552 in mono-microbial (circle) and in dual species biofilms together with *C. albicans* clinical isolate 31883 (triangle) or *C. albicans* SC5314 laboratory strain (square). Shown are the mean cfu’s of *S. aureus* derived from two representative experiments with three intra-assay replicates. Asterisks indicate significant (*p* < 0.001) differences between mono-microbial and dual species biofilms.

doi:10.1371/journal.pone.0135404.g001
Subinhibitory concentrations of farnesol promote biofilm formation of *S. aureus*

In order to further define the growth-promoting activity of *C. albicans* culture supernatants the effect of a number of molecules secreted by *C. albicans* such as farnesol, tyrosol and prostaglandin E2 (PGE2), were tested.

**Fig 2. Growth-promoting properties of cell-free *C. albicans* supernatants.** (a) Supernatants removed from biofilms of two *C. albicans* wild type strains SC5314 and 31883, respectively, after the indicated time of incubation were added to 24h old biofilms of *S. aureus* 19552. (b) Heat-treated (striped) and untreated supernatants (open bars) were collected as described above and added to 24h-old *S. aureus* biofilms. *S. aureus* grown as mono-microbial biofilm was used as control (solid bars). Shown are the mean cfu and the standard deviations of two independent experiments each with three replicates. Asterisks indicate statistically significant differences ($p<0.001$).

doi:10.1371/journal.pone.0135404.g002
Synthetic farnesol at concentrations between 5 and 0.5 nM (Fig 3A), but not purified tyrosol, stimulated the growth of *S. aureus* in biofilms, whereas concentrations ≥ 0.5 μM significantly reduced the growth of *S. aureus* (S1 Fig).

The application of supernatants from cultures of both C. albicans SC5314 (farnesol producer) and ATCC10231 (farnesol nonproducer) significantly enhanced the growth rates of *S. aureus* (Fig 3B). Interestingly, the farnesol-producing strain exhibited a stronger impact to the growth and biofilm formation of *S. aureus* than the farnesol-negative isolate.

**Purified PGE2 stimulates growth of *S. aureus* in biofilms**

Next step was to analyze the effect of purified PGE2 on 24h old *S. aureus* biofilms. As shown in Fig 4A, purified PGE2 significantly enhanced *S. aureus* biofilm formation in a dose-dependent manner. The stimulatory activity of purified PGE2 was neutralized by heating treatment of the PGE2 solution (Fig 4B).

*C. albicans* PGE2-deficient mutant strain do not stimulate growth of *S. aureus*

PGE2 and its metabolites were abundantly detected in culture supernatants of *C. albicans* wt and reference strains, and their amount increased according to the *C. albicans* cell density.

In contrast, PGE2 levels of the *C. albicans* null mutant (ura3-/fet31-/-), deficient in the multi-copper oxidase genes fet31, were below the detection limit of the assay (Fig 5A and S2 Fig).

The concentration of purified PGE2 inducing the growth of *S. aureus* were similar to the PGE2 levels measured in supernatants of *C. albicans* mono-microbial biofilms (Figs 4A and 5A).

To test the hypothesis that PGE2 is responsible for the stimulatory effect of *C. albicans* on *S. aureus* biofilms, the effect of cell-free supernatants derived from PGE2 producers (*C. albicans* SC5314 and *C. albicans* ura3-) and from the PGE2 nonproducer (*C. albicans* ura3-/fet31-) to the growth of *S. aureus* was investigated (Fig 5B). Supernatants derived from the PGE2-deficient mutant were unable to stimulate the growth of *S. aureus*.

Interestingly, the farnesol producer *C. albicans* SC5314 secreted significantly higher levels of PGE2 than the farnesol-deficient strain ATCC10231 (Fig 5C).

**Treatment of mixed biofilms with indomethacin reduced growth of *S. aureus***

In addition, we tested whether the nonspecific cyclooxygenase inhibitor indomethacin can influences the stimulatory activity of *C. albicans* to *S. aureus*. Indomethacin at a concentration between 10 and 1000 pg/mL efficiently blocked the biosynthesis of PGE2 (Fig 6A) and its metabolites (Fig 6B) by *C. albicans*. In cultures of mixed *S. aureus*/*C. albicans* biofilms indomethacin significantly suppressed the growth of *S. aureus* in a dose-dependent manner (Fig 6C).

Experiments performed with the *S. aureus* small colony variant 31338 revealed similar results.

Neither DMSO nor Indomethacin significantly affected the growth of *S. aureus* or *C. albicans*. Data are exemplarily represented for *S. aureus* 19552 and *C. albicans* SC5314 (S3 Fig).
Fig 3. Effect of farnesol on the growth of *S. aureus* 19552 in mono-microbial biofilms. (a) Pre-cultured 24h old *S. aureus* biofilms were supplemented with different concentrations of purified farnesol and the number of cfu’s was determined. *S. aureus* biofilms incubated in farnesol-free medium were used as control. (b) Growth kinetics of *S. aureus* in dual biofilms with the farnesol-deficient *C. albicans* strain ATCC10231 (striped) and the farnesol producer *C. albicans* SC5314 (open bars). Colony forming units (cfu’s) of *S. aureus* derived from single species biofilms were function as control (solid bars). Shown are the mean cfu’s and the standard deviations of two representative experiments with three replicates each. Asterisks indicate significant (p<0.05) differences compared to controls.

doi:10.1371/journal.pone.0135404.g003
**S. aureus** does not stimulate the PGE$_2$ synthesis in *C. albicans*

The levels of PGE$_2$ and of the PGE$_2$ metabolites were not enhanced in dual biofilms of *S. aureus* and *C. albicans* wild type strains compared with *C. albicans* mono-microbial biofilms, indicating that *S. aureus* did not stimulate the release of PGE$_2$ from *C. albicans* isolates (S4 Fig).

---

**Fig 4.** PGE$_2$ stimulates the growth of *S. aureus* biofilms. (a) *S. aureus* 19552 was grown in single species biofilms in the presence of various concentrations of purified PGE$_2$. The mean number of colony forming units (cfu’s) from untreated *S. aureus* biofilms were used as control. Asterisks indicate statistically significant (p < 0.05) differences between PGE$_2$-treated and untreated biofilms. (b) Cultures of *S. aureus* 19552 biofilms were supplemented with heat-treated (solid bars) and untreated (open bars) PGE$_2$ supplemented medium. Shown are the mean number of *S. aureus* cfu’s normalized to the non-supplemented control as well as the standard deviations derived from two independent experiments and three replicates per experiment. Asterisks indicate significant (p < 0.05) differences between the groups.

doi:10.1371/journal.pone.0135404.g004
In polymicrobial infections, biofilm formation is the predominant mode of life [29–31]. Biofilms are structured microbial communities attached to biotic or abiotic surfaces and embedded in a matrix of exopolymers to withstand the host immune response and exhibit increased resistance to antimicrobial agents [32–35]. It is estimated that 27% of nosocomial *C. albicans*...
bloodstream infections are polymicrobial, with S. aureus as the third most common organism isolated in conjunction with C. albicans [36].

In vitro studies demonstrated that the formation of S. aureus biofilms on abiotic materials in the presence of serum requires pre-coating and nutrient supplementation [37]. In order to study the interactions between C. albicans and S. aureus in mono-microbial and dual species biofilms, we have optimized an in vitro biofilm model of infection. Using this model, we observed increased growth rates of S. aureus in dual biofilms in the presence of C. albicans. In
C. albicans PGE₂ Promotes Growth of S. aureus

vitro studies described the formation of S. aureus microcolonies on the surface of biofilms with C. albicans serving as the underlying scaffolding [38,39]. The adherence of S. aureus on fungal hyphae was mediated by the Candida agglutinin-like protein 3 (Als3p; [40]). Studies of the protein expression during the growth of dual C. albicans/S. aureus biofilms identified 27 differentially regulated proteins, mostly involved in growth, metabolism, or stress response. Among the down-regulated staphylococcal proteins was the global transcriptional repressor of virulence factors, CodY, suggesting that the enhanced pathogenesis of S. aureus may not only be due to physical interactions [41,42].

Staib et al. [1] hypothesized the potential existence of C. albicans end-products as a substrate for a favorable growth of S. aureus. One of the C. albicans products continuously excreted in the environment is farnesol a quorum sensing molecule involved in the regulation of the fungal yeast-mycelium dimorphism. At high levels, farnesol has been shown to exhibit antimicrobial activity against various pathogens [12]. Kaneko et al. reported growth inhibition of fungal yeast-mycelium dimorphism. At high levels, farnesol has been shown to exhibit antimicrobial activity against various pathogens [12]. Kaneko et al. reported growth inhibition of S. aureus at concentrations of 40 μg mL⁻¹ (equivalent to 180 μM) which is concordant with our results [43]. In this study, subinhibitory concentrations of farnesol (0.5–5 nM) promoted the biofilm formation of S. aureus, an effect already described for several antimicrobial agents [44–47]. In stationary phase cultures of C. albicans, farnesol accumulated at levels between 2 and 4 μM [8,48]. In addition, our data showed that S. aureus biofilm production was propagated by the farnesol-deficient C. albicans strain ATCC 10231 albeit at a lower level compared to the farnesol producer C. albicans SC5314, whereas the PGE₂ null mutant did not enhance the growth of S. aureus. Unlike SC5314, ATCC10231 excreted significantly lower levels of PGE₂ in this experimental setting indicating that the differences in the growth-stimulating effect to S. aureus resulted from the PGE₂ levels. In conclusion, it appears that PGE₂ has a superior role in the induction of S. aureus biofilm formation as compared to farnesol, which, however, also supports the growth of S. aureus at low concentrations.

We demonstrated for the first time that C. albicans PGE₂ may be one of the suggested end-products presumed by Staib [1]. As shown in this study, the stimulatory effect to the growth of S. aureus was not observed, when C. albicans supernatants or medium supplemented with purified PGE₂ were heat treated suggesting that PGE₂ is heat-sensitive. This observation is concordant with the results described by Carlson who reported increased mortality rates of mice co-infected with sublethal doses of C. albicans and S. aureus [3]. This effect could not be reproduced when either of the agents was heat inactivated.

Endogenous PGE₂ maintains the integrity of the mucosal barrier in the lungs and in the gastrointestinal tract [49–51]. Mucus accumulation and overexpression of inflammatory response genes are relevant pathogenic features of cystic fibrosis (CF), a genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator gene cftr [52]. Recently, Harmon et al. demonstrated a defective peroxisome proliferator-activated receptor (PPARγ) function in epithelial cells which was caused by the decreased conversion of PGE₂ to the PPARγ ligand 15-keto-PGE₂ leading to the accumulation of PGE₂ [51]. As elevated levels of PGE₂ have been detected in respiratory tract samples of patients suffering from cystic fibrosis [53,54] and in consideration of the results from this study, it seems to be possible that enhanced PGE₂ levels may contribute to the early airway colonization due to S. aureus in patients with CF.

PGE₂ was demonstrated to induce germ tube formation and to be involved in biofilm formation by C. albicans [55,56] suggesting C. albicans PGE₂ to be a potential virulence factor. Despite induced endocytosis by host cells at the early stage of infection, hyphal mediated active penetration of the host tissue is the major route of invasion [57,58]. Tissue invasion by C. albicans is associated with cytokine secretion, inducing host immune response mechanisms. Phagocytosis by macrophages and neutrophils represents the first line of defense against
Candida infections but intracellular killing is not always effective. One of the underlying mechanisms is the inhibition of the phagosome maturation and the nitric oxid (NO) production in macrophages after infection with \(C. albicans\) [59], an effect that may be resulted from candidal PGE\(_2\) excretion.

PGE\(_2\) is a critical molecule that regulates the activation, maturation, migration, and cytokine secretion of several immune cells, particular those of the innate immunity. In the context of infection, endogenous PGE\(_2\) inhibits the cytolytic effector function of natural killer (NK) cells, the activation, migration and production of proteolytic enzymes in granulocytes and limits the phagocytosis and pathogen-killing function of alveolar macrophages (reviewed by [14,18]. Aronoff et al. reported the negative regulatory role of endogenously produced and exogenously added PGE\(_2\) on FcR\(\gamma\)-mediated phagocytosis of bacterial pathogens by alveolar macrophages suggesting that PGE\(_2\) derived from \(C. albicans\) may impair the local host innate immunity [60]. This suggestion is underlined by the investigations of Roux et al. who had shown that airway colonization with \(C. albicans\) inhibited phagocytosis of \(S. aureus\) and \(P. aeruginosa\) and enhanced the prevalence of bacterial pneumonia, which was reduced by antifungal treatment [61,62].

Mice inoculated with either \(S. aureus\) or \(C. albicans\) survived infection, whereas combined infection with both pathogens enhanced the mortality rate to 40–100% [3,4]. Reversely, enhanced microbial clearance and survival was demonstrated in studies with COX-2-deficient mice [63–65]. This is in line with our observation that a mutant strain of \(C. albicans\) deficient in PGE\(_2\) production did not promote the growth of \(S. aureus\). Furthermore, in this study the non-selective cyclooxygenase (COX) inhibitor indomethacin that blocked PGE\(_2\) biosynthesis by \(C. albicans\) also reduced the growth of \(S. aureus\) in dual biofilms to a level observed in mono-microbial \(S. aureus\) biofilms.

Thus, treatment with indomethacin or with antifungal agents may exhibit several positive effects in patients with dual \(S. aureus\)/\(C. albicans\) infections [51,60–62].

Finally, in this study \(S. aureus\) did not enhanced the biofilm thickness of \(C. albicans\) and its PGE\(_2\) synthesis in dual biofilms compared with mono-microbial \(C. albicans\) biofilms, although bacterial peptidoglycan-derived molecules have been shown to promote \(C. albicans\) hyphal growth [66,67]. Thus, in mixed biofilms the impact of \(S. aureus\) to \(C. albicans\) remained unclear.

**Conclusion**

Our findings indicate that PGE\(_2\) is the key molecule stimulating the growth and biofilm formation of \(S. aureus\) in dual \(S. aureus\)/\(C. albicans\) biofilms, although subinhibitory farnesol concentrations may also support this effect. Candidal PGE\(_2\) may exhibit a dual effect in \(S. aureus\)/\(C. albicans\) polymicrobial biofilms, first, by promoting fungal hyphal formation and second, by providing a proper substratum for the proliferation of \(S. aureus\). Further characterization of the intricate interaction between these pathogens is warranted, as it may aid in the design of further therapeutic strategies against polymicrobial biofilm infections.

**Supporting Information**

S1 Fig. Effect of farnesol on the growth of \(S. aureus\).
(TIF)

S2 Fig. PGE\(_2\) metabolite synthesis in \(C. albicans\) wt strains.
(TIF)
S3 Fig. Indomethacin and DMSO does not affect the growth of (a) *S. aureus* or (b) *C. albicans*. (TIF)

S4 Fig. *S. aureus* does not stimulate the PGE2 synthesis in *C. albicans*. (TIF)

**Acknowledgments**

We thank Sascha Brunke (Hans Knoell Institute, Jena, Germany) for generously providing us with *C. albicans* M35, M134 and M1096 strains.

**Author Contributions**

Conceived and designed the experiments: IT. Performed the experiments: JK IT. Analyzed the data: IT JK GG. Contributed reagents/materials/analysis tools: JK IT GG. Wrote the paper: IT GG JK.

References

1. Staib F, Grosse G, Mishra SK. Staphylococcus aureus and Candida albicans infection (animal experiments). Zentralbl Bakteriol. 1976; 234: 450–461.
2. deRepentigny J, Levesque R, Mathieu LG. Increase in the in vitro susceptibility of Staphylococcus aureus to antimicrobial agents in the presence of Candida albicans. Can J Microbiol. 1979; 25: 429–435. PMID: 385127
3. Carlson E. Synergistic effect of Candida albicans and Staphylococcus aureus on mouse mortality. Infect Immun. 1982; 38: 921–924. PMID: 7152678
4. Peters BM, Noverr MC. Candida albicans-Staphylococcus aureus polymicrobial peritonitis modulates host innate immunity. Infect Immun. 2013; 81: 2178–2189. doi: 10.1128/IAI.00265-13 PMID: 23545303
5. Hogan DA, Vik A, Kolter R. A Pseudomonas aeruginosa quorum-sensing molecule influences Candida albicans morphology. Mol Microbiol. 2004; 54: 1212–1223. PMID: 15554963
6. Kerr JR. Suppression of fungal growth exhibited by Pseudomonas aeruginosa. J Clin Microbiol. 1994; 32: 525–527. PMID: 8150966
7. Gupta N, Haque A, Mukhopadhyay G, Narayan RP, Prasad R. Interactions between bacteria and Candida in the burn wound. Burns. 2005; 31: 375–376. PMID: 15774298
8. Hornby JM, Jensen EC, Lisek AD, Tasto JJ, Jahnke B, Shoemaker R, et al. Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol. Appl Environ Microbiol. 2001; 67: 2982–2992. PMID: 11425711
9. Ramage G, Saville SP, Wickes BL, Lopez-Ribot JL. Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule. Appl Environ Microbiol. 2002; 68: 5459–5463. PMID: 12406738
10. Alem MA, Oteef MD, Flowers TH, Douglas LJ. Production of tyrosol by Candida albicans biofilms and its role in quorum sensing and biofilm development. Eukaryot Cell. 2006; 5: 1770–1779. PMID: 16980403
11. Cugini C, Calfee MW, Farrow JM III, Morales DK, Pesci EC, Hogan DA. Farnesol, a common sesquiterpene, inhibits PQS production in Pseudomonas aeruginosa. Mol Microbiol. 2007; 65: 896–906. PMID: 17640272
12. Jabra-Rizk MA, Meiller TF, James CE, Shirliff ME. Effect of farnesol on Staphylococcus aureus biofilm formation and antimicrobial susceptibility. Antimicrob Agents Chemother. 2006; 50: 1463–1469. PMID: 16569866
13. Kuroda M, Nagasaki S, Ito R, Ohta T. Sesquiterpene farnesol as a competitive inhibitor of lipase activity of Staphylococcus aureus. FEMS Microbiol Lett. 2007; 273: 28–34. PMID: 17559400
14. Agard M, Asakrah S, Morici LA. PGE(2) suppression of innate immunity during mucosal bacterial infection. Front Cell Infect Microbiol. 2013; 3: 45. doi: 10.3389/fcimb.2013.00045 PMID: 23971009
15. Obermajer N, Wong JL, Edwards RP, Odunsi K, Moysich K, Kalinski P. PGE(2)-driven induction and maintenance of cancer-associated myeloid-derived suppressor cells. Immunol Invest. 2012; 41: 635–657. doi: 10.3109/08820139.2012.695417 PMID: 23017139
16. Bankhurst AD. The modulation of human natural killer cell activity by prostaglandins. J Clin Lab Immunol. 1982; 7: 85–91. PMID: 6951051

17. Goto T, Herberman RB, Maluish A, Strong DM. Cyclic AMP as a mediator of prostaglandin E-induced suppression of human natural killer cell activity. J Immunol. 1983; 130: 1350–1355. PMID: 6185577

18. Kalinski P. Regulation of Immune Responses by Prostaglandin E-2. Journal of Immunology 2012; 188: 21–28.

19. Erb-Downward JR, Noverr MC. Characterization of prostaglandin E2 production by Candida albicans. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother. 2009; 53: 3914–3922. doi:10.1128/AAC.00657-09 PMID: 19564370

20. Gillum AM, Tsay EY, Kirsch DR. Isolation of the Candida albicans gene for orotidine-5'-phosphate decarboxylase by complementation of S. cerevisiae ure3 and E. coli pyrF mutations. Mol Gen. 1984; 198: 179–182. PMID: 6394964

21. Fonzi WA, Irwin MY. Isoenic strain construction and gene mapping in Candida albicans. Genetics 1993; 134: 717–728. PMID: 8349105

22. Fradin C, De Groote P, Mac Callum D, Schaller M, Odds FC, et al. Granulocytes govern the transcriptional response, morphology and proliferation of Candida albicans in human blood. Mol Microbiol. 2005; 56: 397–415. PMID: 15813733

23. Eck R, Hundt S, Hartl A, Roemer E, Kunkel W. A multicopper oxidase gene from Candida albicans: cloning, characterization and disruption. Microbiology 1999; 145 (Pt 9): 2415–2422. PMID: 10517594

24. Musken M, Di FS, Romling U, Haussler S. A 96-well-plate-based optical method for the quantitative and qualitative evaluation of Pseudomonas aeruginosa biofilm formation and its application to susceptibility testing. Nat Protoc. 2010; 5: 1460–1469. doi: 10.1038/nprot.2010.110 PMID: 20671729

25. Harrison JJ, Stremick CA, Turner RJ, Allan ND, Olson ME, Ciri H. Microtiter susceptibility testing of microbes growing on peg lids: a miniaturized biofilm model for high-throughput screening. Nat Protoc. 2010; 5: 1236–1254. doi:10.1038/nprot.2010.71 PMID: 20959953

26. Chen P, Abercrombie JJ, Jeffrey NR, Leung KP. An improved medium for growing Staphylococcus aureus biofilm. J Microbiol Methods. 2012; 90: 115–118. doi: 10.1016/j.mimet.2012.04.009 PMID: 22542521

27. Efthimiadis A, Spanevello A, Hamid Q, Kelly MM, Linden M, Louis R, et al. Methods of sputum processing for cell counts, immunocytochemistry and in situ hybridisation. Eur Respir J Suppl. 2002; 37: 19s–23s. PMID: 12361358

28. Peeters E, Nelis HJ, Coenye T. Comparison of multiple methods for quantification of microbial biofilms grown in microtiter plates. J Microbiol Methods. 2008; 72: 157–165. PMID: 18155789

29. Douglas LJ. Candida biofilms and their role in infection. Trends Microbiol. 2003; 11: 30–36. PMID: 12526852

30. El-Azizi MA, Starks SE, Khordori N. Interactions of Candida albicans with other Candida spp. and bacteria in the biofilms. J Appl Microbiol. 2004; 96: 1067–1073. PMID: 15078523

31. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284: 1318–1322. PMID: 10334980

32. Ramage G, Bachmann S, Patterson TF, Wickes BL, Lopez-Ribot JL. Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J Antimicrob Chemother. 2002; 49: 973–980. PMID: 12039889

33. Ramage G, Vandewalle K, Bachmann SP, Wickes BL, Lopez-Ribot JL. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time–kill studies. Antimicrob Agents Chemother. 2002; 46: 3634–3636. PMID: 12384379

34. Ramage G, Wickes BL, Lopez-Ribot JL. Biofilms of Candida albicans and their associated resistance to antifungal agents. Am Clin Lab. 2001; 20: 42–44. PMID: 11570274

35. Lewis K. Riddle of biofilm resistance. Antimicrobial Agents and Chemotherapy. 2001; 45: 999–1007. PMID: 11257008

36. Klotz SA, Chasin BS, Powell B, Gaur NK, Lipke PN. Polymicrobial bloodstream infections involving Candida species: analysis of patients and review of the literature. Diagn Microbiol Infect Dis. 2007; 59: 401–406. PMID: 17886612

37. Cassat JE, Lee CY, Smeltzer MS. Investigation of biofilm formation in clinical isolates of Staphylococcus aureus. Methods Mol Biol. 2007; 391: 127–144. PMID: 18025674

38. Harriott MM, Noverr MC. Candida albicans and Staphylococcus aureus form polymicrobial biofilms: effects on antimicrobial resistance. Antimicrobial Agents Chemother. 2009; 53: 3914–3922. doi: 10.1128/AAC.00657-09 PMID: 19564370

39. Carlson E, Johnson G. Protection by Candida albicans of Staphylococcus aureus in the establishment of dual infection in mice. Infect Immun. 1985; 50: 655–659. PMID: 3905609
40. Peters BM, Ovchinnikova ES, Krom BP, Schlecht LM, Zhou H, Hoyer LL, et al. Staphylococcus aureus adherence to Candida albicans hyphae is mediated by the hyphal adhesin Als3p. Microbiology 2012; 158: 2975–2986. doi: 10.1099/mic.0.062109-0 PMID: 22918893

41. Ovchinnikova ES, Krom BP, Busscher HJ, van der Mei HC. Evaluation of adhesion forces of Staphylococcus aureus along the length of Candida albicans hyphae. BMC Microbiol. 2012; 12: 281. doi: 10.1186/1471-2180-12-281 PMID: 23181353

42. Peters BM, Jabra-Rizk MA, Scheper MA, Leid JG, Costerton JW, Shirtliff ME. Microbial interactions and differential protein expression in Staphylococcus aureus-Candida albicans dual-species biofilms. FEMS Immunol Med Microbiol. 2010; 59: 493–503. doi: 10.1111/j.1574-695X.2010.00710.x PMID: 20606978

43. Kaneko M, Togashi N, Hamashima H, Hirohara M, Inoue Y. Effect of farnesol on mevalonate pathway of Staphylococcus aureus. J Antibiot (Tokyo) 2011; 64: 547–549.

44. Tammer I, Reuner J, Hartig R, Geginat G. Induction of Candida albicans biofilm formation on silver-coated vascular grafts. J Antimicrob Chemother. 2014; 69: 1282–1285. doi: 10.1093/jac/dkt521 PMID: 24448486

45. Kaplan JB, Jabbouri S, Sadovskaya I. Extracellular DNA-dependent biofilm formation by Staphylococcus aureus. J Med Microbiol. 2009; 58: 1705–1711. doi: 10.1099/jmm.0.01274.x PMID: 19751

46. Boucher RC. Airway surface dehydratation in cystic fibrosis: pathogenesis and therapy. Annu Rev Med. 2007; 58: 157–170. PMID: 17217330

47. Lucidi V, Ciabattoni G, Bella S, Barnes PJ, Montuschi P. Exhaled 8-isoprostane and prostaglandin E(2) in patients with stable and unstable cystic fibrosis. Free Radic Biol Med. 2008; 45: 913–919. doi: 10.1016/j.freeradbiomed.2008.06.026 PMID: 18634869

48. Fernandez-Arenas E, Bleck CK, Nombela C, Gil C, Griffiths G, Diez-Orejas R. Candida albicans actively modulates intracellular membrane trafficking in mouse macrophage phagocytes. Cell Microbiol. 2009; 11: 560–589. doi: 10.1111/j.1462-5822.2008.01274.x PMID: 19134116

49. Ronoff DM, Canetti C, Peters-Golden M. Prostaglandin E2 inhibits alveolar macrophage phagocytosis through an E-prostanoid 2 receptor-mediated increase in intracellular cyclic AMP. J Immunol. 2004; 173: 559–565. PMID: 15210617

50. Roux D, Gaudry S, Khoy-Ear L, Aloulou M, Phillips-Houlbracq M, Bex J, et al. Airway fungal colonization compromises the immune system allowing bacterial pneumonia to prevail. Crit Care Med. 2013; 41: e191–e199. doi: 10.1097/CCM.0b013e31828a25d6 PMID: 23887232
62. Roux D, Gaudry S, Dreyfuss D, El-Benna J, de Prost N, Denamur E, et al. Candida albicans impairs macrophage function and facilitates Pseudomonas aeruginosa pneumonia in rat. Crit Care Med. 2009; 37: 1062–1067. doi: 10.1097/CCM.0b013e31819629d2 PMID: 19237918

63. Bowman CC, Bost KL. Cyclooxygenase-2-mediated prostaglandin E2 production in mesenteric lymph nodes and in cultured macrophages and dendritic cells after infection with Salmonella. J Immunol. 2004; 172: 2469–2475. PMID: 14764719

64. Ejima K, Layne MD, Carvajal IM, Kritek PA, Baron RM, Chen YH, et al. Cyclo-oxygenase-2-deficient mice are resistant to endotoxin-induced inflammation and death. FASEB J. 2003; 17: 1325–1327. PMID: 12738799

65. Sadikot RT, Zeng H, Azim AC, Joo M, Dey SK, Breyer RM, et al. Bacterial clearance of Pseudomonas aeruginosa is enhanced by the inhibition of COX-2. Eur J Immunol. 2007; 37: 1001–1009. PMID: 17330822

66. Wang Y, Xu XL. Bacterial peptidoglycan-derived molecules activate Candida albicans hyphal growth. Commun Integr Biol. 2008; 1: 137–139. PMID: 19704871

67. Xu XL, Lee RTH, Fang HM, Wang YM, Li R, Zou H, et al. Bacterial peptidoglycan triggers Candida albicans hyphal growth by directly activating the adenylyl cyclase Cyr1p. Cell Host & Microbe 2008; 4: 28–39.